# A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

> **NCT06173518** · PHASE1 · RECRUITING · sponsor: **Autolus Limited** · enrollment: 30 (estimated)

## Conditions studied

- Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** AUTO1

## Key facts

- **NCT ID:** NCT06173518
- **Lead sponsor:** Autolus Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-16
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06173518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06173518, "A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06173518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*